Ticker >

Lasa Supergenerics share price

Lasa Supergenerics Ltd.

NSE: LASA BSE: 540702 SECTOR: Pharmaceuticals & Drugs  21k   49   4

25.47
-0.06 (-0.24%)
BSE: 26 Apr 04:01 PM

Price Summary

Today's High

₹ 26.09

Today's Low

₹ 25.4

52 Week High

₹ 40.95

52 Week Low

₹ 20.1

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

127.61 Cr.

Enterprise Value

146.99 Cr.

No. of Shares

5.01 Cr.

P/E

0

P/B

1.14

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  22.33

CASH

2.39 Cr.

DEBT

21.77 Cr.

Promoter Holding

53.65 %

EPS (TTM)

₹  -4.28

Sales Growth

-5.51%

ROE

-27.97 %

ROCE

-23.94%

Profit Growth

-624.41 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5.51%
3 Year-8.16%
5 Year-11.86%

Profit Growth

1 Year-624.41%
3 Year-319.97%
5 Year-225.63%

ROE%

1 Year-27.97%
3 Year-5.39%
5 Year-4.81%

ROCE %

1 Year-23.94%
3 Year-3.4%
5 Year-1.43%

Debt/Equity

0.184

Price to Cash Flow

-7.38

Interest Cover Ratio

-9.07847672644029

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 53.65 20.66
Dec 2023 53.65 20.66
Sep 2023 53.65 20.66
Jun 2023 53.65 20.66
Mar 2023 53.65 20.66
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 20.1098672947704 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 35.3940207278961.

 Limitations

  • The company has shown a poor profit growth of -319.972468085495% for the Past 3 years.
  • The company has shown a poor revenue growth of -8.15863923816468% for the Past 3 years.
  • Company has a poor ROE of -5.38961595455862% over the past 3 years.
  • Company has a poor ROCE of -3.40215165596836% over the past 3 years
  • Company has low Interest coverage ratio of -9.07847672644029.
  • Company has negative cash flow from operations of -17.3004.
  • Promoter pledging is high as 20.66%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 31.71 35.32 30.56 24.3 26.66
Total Expenditure 34.17 30.98 26.51 23.26 25.61
Operating Profit -2.46 4.34 4.05 1.04 1.05
Other Income 0.86 0.93 0 0.08 0
Interest 0.43 0.42 0.37 0.56 0.44
Depreciation 3.09 4.17 2.65 2.68 2.68
Exceptional Items 0 -19.9 0 0 0
Profit Before Tax -5.12 -19.21 1.03 -2.11 -2.06
Tax -0.2 -4.21 5.98 -2.09 -0.61
Profit After Tax -4.92 -15 -4.95 -0.02 -1.46
Adjusted EPS (Rs) -1.21 -2.99 -0.99 0 -0.29

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 169.57 167.26 202.38 137.13 129.57
Total Expenditure 158.52 137.29 155.17 121.11 136.17
Operating Profit 11.05 29.97 47.21 16.02 -6.6
Other Income 0.54 0.23 0.18 0.28 1.84
Interest 8.38 8.12 2.06 0.06 4.19
Depreciation 19.31 17.34 15.82 14.51 13.42
Exceptional Items 0 0 0 -7.86 -19.9
Profit Before Tax -16.1 4.74 29.49 -6.14 -42.27
Tax -4.07 1.11 6.71 -0.81 -3.64
Net Profit -12.03 3.63 22.78 -5.33 -38.62
Adjusted EPS (Rs.) -5.26 0.89 5.6 -1.06 -7.71

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 22.86 40.67 40.67 50.1 50.1
Total Reserves 82.43 100.79 118.24 107.78 68.18
Borrowings 45.72 14.14 0 0 0
Other N/C liabilities -2.66 -2.71 8.41 6.54 2.84
Current liabilities 107.12 75.92 40.54 44.75 42.73
Total Liabilities 255.47 228.81 207.86 209.17 163.85
Assets
Net Block 161.69 152.19 142.95 137.28 118.96
Capital WIP 6.96 0 0 4.58 4.64
Intangible WIP 0.25 0 0 0 0
Investments 0 0 0 0.38 0.39
Loans & Advances 0.74 0.75 0.59 0.63 0.64
Other N/C Assets 0 0 0 0 0
Current Assets 85.84 75.87 64.32 66.3 39.22
Total Assets 255.47 228.81 207.86 209.17 163.85
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -16.1 4.74 29.49 1.72 -22.37
Adjustment 27.2 25.27 17.75 6.5 -4.07
Changes in Assets & Liabilities 33.11 -16.01 -5.93 3.59 9.18
Tax Paid -3.54 -0.37 0 -2.59 -0.04
Operating Cash Flow 40.66 13.62 41.31 9.21 -17.3
Investing Cash Flow -7.34 -1.63 -3.6 -2.91 11.19
Financing Cash Flow -33.4 -9.85 -36.44 -0.04 -4.16
Net Cash Flow -0.08 2.15 1.27 6.26 -10.27

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 53.65 53.65 53.65 53.65 53.65
omkar pravin herlekar 53.65 53.65 53.65 - 53.65
omkar pravin herleker - - - 53.65 -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 46.35 46.35 46.35 46.35 46.35
anil vishanji dedhia - - 1.80 - 1.30
bnp enterprises 8.48 8.48 - 8.48 8.48
bebi dharma padhir - - 8.48 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

Lasa Supergenerics - Quaterly Results13 Feb 2024, 6:26PM Lasa Supergenerics - Quaterly Results9 Jun 2023, 4:46PM Lasa Supergenerics - Quaterly Results9 Jun 2023, 4:46PM Lasa Supergenerics - Quaterly Results9 Jun 2023, 4:46PM Lasa Supergenerics informs about postponement of board meeting7 Jun 2023, 4:58PM Lasa Supergenerics informs about disclosure of related party transactions28 Nov 2022, 4:43PM Lasa Supergenerics informs about outcome of board meeting 26 Aug 2022, 4:45PM Lasa Supergenerics - Quaterly Results8 Aug 2022, 3:13PM Lasa Supergenerics - Quaterly Results8 Aug 2022, 3:13PM Lasa Supergenerics secures new order of Rs 50 crore from just 5 customers27 Apr 2022, 10:30AM Lasa Supergenerics reports over 3-fold jump in Q4 net profit12 Apr 2022, 12:07PM Lasa Supergenerics informs about press release11 Apr 2022, 4:55PM Lasa Supergenerics - Quaterly Results11 Apr 2022, 1:17PM Lasa Supergenerics - Quaterly Results11 Apr 2022, 1:17PM Lasa Supergenerics - Quaterly Results11 Apr 2022, 1:17PM Lasa Supergenerics informs about board meeting21 Mar 2022, 9:45AM Lasa Supergenerics files another suit for permanent injunction against one of its competitors10 Mar 2022, 9:59AM Lasa Supergenerics - Quaterly Results7 Feb 2022, 3:41PM Lasa Supergenerics - Quaterly Results7 Feb 2022, 3:41PM Lasa Supergenerics - Quaterly Results7 Feb 2022, 3:41PM Lasa Supergenerics informs about disclosure4 Feb 2022, 10:02AM Lasa Supergenerics informs about press release16 Dec 2021, 9:30AM Lasa Supergenerics resumes operations in all units situated in Mahad, Chiplun23 Aug 2021, 2:34PM Lasa Supergenerics reports 85% fall in Q1 net profit18 Aug 2021, 12:12PM Lasa Supergenerics board approves financial results16 Aug 2021, 1:42PM Lasa Supergenerics informs about board meeting6 Aug 2021, 2:49PM Lasa Supergenerics informs about press release26 Jul 2021, 4:24PM Lasa Supergenerics informs about press release9 Jun 2021, 2:47PM Lasa Supergenerics launches new product Oxyclozanide9 Jun 2021, 12:15PM Lasa Supergenerics informs about earnings call1 Jun 2021, 4:35PM Lasa Supergenerics informs about outcome of board meeting31 May 2021, 4:18PM Lasa Supergenerics informs about PCS certificate26 Apr 2021, 3:58PM Lasa Supergenerics submits RTA certificate18 Jan 2021, 1:52PM Lasa Supergenerics gets WHO Certificate of Good Manufacturing Practices for Khed unit 12 Jan 2021, 12:40PM Lasa Supergenerics gets environmental clearance for Benzimidazole Derivatives Capacity Expansion 4 Nov 2020, 12:42PM Lasa Supergenerics informs about media release8 Jun 2020, 10:37AM Lasa Supergenerics gets FDA’s nod to manufacture Progesterone013 Apr 2020, 9:21AM

Lasa Supergenerics Stock Price Analysis and Quick Research Report. Is Lasa Supergenerics an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lasa Supergenerics and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Lasa Supergenerics cash from the operating activity was Rs -17.3004 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lasa Supergenerics has a Debt to Equity ratio of 0.184 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lasa Supergenerics , the EPS growth was -624.414998590358 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lasa Supergenerics has OPM of -5.09324075889225 % which is a bad sign for profitability.
     
  • ROE: Lasa Supergenerics have a poor ROE of -27.9689189976996 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Lasa Supergenerics is Rs 25.55. One can use valuation calculators of ticker to know if Lasa Supergenerics share price is undervalued or overvalued.
Last Updated on:
Brief about Lasa Supergenerics
X